CD274 and neoplasm: Based on these results, pembrolizumab has been approved by the US Food and Drug Administration (FDA) for patients with GAC positive for PD-L1 expression (≥1% labeling index in tumor/immune cells in the presence of at least 100 tumor cells in the specimen) to be used in the third (or later) line.